Abstract
Purpose: Adverse reactions reported in patients treated with antibody-calicheamicin conjugates such as gemtuzumab ozogamicin (Mylotarg) and inotuzumab......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
